{"id":"W2991659810","doi":"10.1016/j.jaad.2019.11.040","title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials","year":2019,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":91,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Janssen Research and Development; LEO Pharma; Janssen Scientific Affairs; Janssen Pharmaceuticals; Celgene; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; Biogen","keywords":"Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Clinical trial; Internal medicine; Placebo; Dermatology; Skin cancer; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00122765,0.0001745756,0.001733016,0.00007899067,0.00004196633,0.000003383035,0.0002720641,0.000134731,0.00001494915],"category_scores_gemma":[0.0005895586,0.00007988724,0.0001929873,0.0001424471,0.001199561,0.00003658925,0.00007684208,0.0002333882,0.000003615593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001994983,"about_ca_system_score_gemma":0.0001641285,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001124155,"about_ca_topic_score_gemma":0.00001237726,"domain_scores_codex":[0.995945,0.002213049,0.001354432,0.0002089711,0.00008263294,0.0001959545],"domain_scores_gemma":[0.9922125,0.00427539,0.003140358,0.0002441064,0.00008480364,0.00004285652],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3924124,0.0005408878,0.3857057,0.00003802299,0.007755657,0.00007916944,0.004872548,0.00001408491,0.1461186,0.0001916324,0.004378715,0.05789264],"study_design_scores_gemma":[0.02026358,0.005431846,0.8963403,0.000324626,0.001213344,0.001933072,0.002355417,0.000001618254,0.0557816,0.00002939029,0.01615762,0.0001675961],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916719,0.001553733,0.000008664478,0.005708514,0.0001414565,0.0004811419,0.0003933893,0.000003297859,0.00003794777],"genre_scores_gemma":[0.9978855,0.0009277363,0.0005208199,0.0002761604,0.00001697378,0.000004574245,0.000003278621,0.00001147236,0.0003534634],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5106346,"threshold_uncertainty_score":0.4419833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03350037897020353,"score_gpt":0.3140369355287464,"score_spread":0.2805365565585429,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}